Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral arterial intervention cases in Maine: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 455 | 39% |
| 2020 | 3 | 414 | 46% |
| 2021 | 5 | 381 | 51% |
| 2022 | 2 | 339 | 56% |
| 2023 | 2 | 291 | 59% |
| 2024 | 1 | 227 | 62% |
| 2025 forecast | – | 226 192–267 | 63% |
| 2026 forecast | – | 230 183–292 | 63% |
| 2027 forecast | – | 231 174–309 | 64% |
| 2028 forecast | – | 232 167–324 | 64% |
| 2029 forecast | – | 233 162–339 | 65% |
| 2030 forecast | – | 234 157–352 | 65% |
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Maine; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2019, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 97 | 12,473+0.3%/yr | +0.3%/yr | 6.5 | 60% | 16,500 in 2030+4.8%/yr |
| New Jersey | 55 | 8,544+2.5%/yr | +2.5%/yr | 7.8 | 77% | 12,500 in 2030+6.5%/yr |
| Pennsylvania | 34 | 5,017−9.7%/yr | −9.7%/yr | 3.5 | 15% | 5,100 in 2030+0.3%/yr |
| Massachusetts | 34 | 3,442−4.1%/yr | −4.1%/yr | 3.5 | 43% | 4,130 in 2030+3.1%/yr |
| Connecticut | 14 | 1,625−9.1%/yr | −9.1%/yr | 4.7 | 71% | 1,530 in 2030−1%/yr |
| New Hampshire | 5 | 493−11%/yr | −11%/yr | 2.1 | 0% | 1,150 in 2030+15%/yr |
| Rhode Island | 4 | 351−12%/yr | −12%/yr | 3.6 | 54% | 380 in 2030+1.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 4 | 343−14%/yr | −14%/yr | 2.30.4× | 5% | 390 in 2030+2.3%/yr |
| Superficial venous ablation | 3 | 189−9.2%/yr | −9.2%/yr | 1.10.3× | 100% | 430 in 2030+15%/yr |
| Carotid revascularization | 0 | 135−5.5%/yr | −5.5%/yr | 0.80.9× | 0% | 560 in 2030+27%/yr |
Peripheral arterial intervention in every state, and its device makers · Every procedure market in Maine · Every state · Compare with New York
Philips leads with 42% of company spending on these surgeons in 2025, +42 pts on 2024.
In 2025, 7 companies reported engagement with Maine’s surgeons worth $2,518 in consulting, speaking, meals and travel tied to these products, about $2,518 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.